Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

HEALTH MEDIA NOW-DR. DAVID HAVA-TRENDS TO WATCH IN INHALED DRUG DELIVERY

  • Broadcast in Health
Health Media Now

Health Media Now

×  

Follow This Show

If you liked this show, you should follow Health Media Now.
h:544015
s:9614323
archived

Please join us this Thursday, November17, 2016 at 4:00 p.m. PST and 7:00 p.m. EST for a live show with host Denise Messenger.  Our special guest is Dr. David Hava.  He is the Chief Scientific Officer at Pulmatrix Inc.  As CSO, Dr. Hava leads the Research and Development organization in the development of inhalation products in the iSPERSE dry powder delivery platform. In addition, Dr. Hava directs and manages the company’s therapeutic strategy to identify and prioritize drug targets and drugs that are enabled by the iSPERSE dry powder delivery platform.  Dr. Hava joined Pulmatrix in 2006 as one of the first Senior Scientists and has been involved in the early stage research and development programs that identified and characterized several of the key aspects of the Pulmatrix technology.  Dr. Hava earned his PhD. in Molecular Biology and Microbiology at Tufts University and completed his post-doctoral training studying immunology and host-pathogen interactions at Harvard Medical School.
 

Comments